Lukas Scheibler - Apr 5, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
CHIEF INNOVATION OFFICER
Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol
APLS
Transactions as of
Apr 5, 2022
Transactions value $
-$28,158
Form type
4
Date filed
4/6/2022, 04:10 PM
Previous filing
Apr 5, 2022
Next filing
May 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $8.43K +609 +1.17% $13.85 52.8K Apr 5, 2022 Direct F1
transaction APLS Common Stock Sale -$36.6K -609 -1.15% $60.09 52.2K Apr 5, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -609 -1.22% $0.00 49.4K Apr 5, 2022 Common Stock 609 $13.85 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from 10B5-1 trading plan.
F2 The sale price range within $1.00. Min. $60.00 - Max. $60.16.
F3 This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.